Sugi Predict

Sugi Predict / Compounds / SCHEMBL4907597

SCHEMBL4907597

SCHEMBL4907597

CCOC(=O)Cc1csc(-c2ccc(F)cc2)n1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.67
▸ MAPT P10636 3/20 0.61
▸ MEN1 O00255 2/20 0.60
▸ KMT2A Q03164 2/20 0.60
▸ ALDH1A1 P00352 6/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ CYP2C9 P11712 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ TP53 P04637 2/20 0.52
▸ USP2 O75604 1/20 0.52
▸ KDM4E B2RXH2 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ GAA P10253 1/20 0.52
▸ TRPM8 Q7Z2W7 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3374076 0.89 MEN1 (0.57) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL4907281 0.87 LMNA (0.56) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL2073208 0.87 MAPT (0.65) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL11157975 0.87 MEN1 (0.62) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL6311629 0.86 MAPT (0.66) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL4905943 0.86 POLB (0.62) LMNAMAPTMEN1KMT2ATP53
SCHEMBL7971165 0.86 MEN1 (0.53) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL2075250 0.86 ALDH1A1 (0.72) MAPTMEN1KMT2AALDH1A1TP53
SCHEMBL4906987 0.85 SMN1; SMN2 (0.53) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL4900722 0.84 MAPT (0.53) LMNAMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12527776-B2 Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) GENZYME CORPORATION (US) 2026-01-20 — — US disclosed
WO-2025262570-A1 VENGLUSTAT AS AN INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE IN SUBJECTS HAVING HEPATIC IMPAIRMENT GENZYME CORPORATION (US) 2025-12-26 — — WO disclosed
EP-4626424-A1 VENGLUSTAT IN COMBINATION WITH A STRONG OR MODERATE INHIBITOR OF CYP3A4 GENZYME CORPORATION (US) 2025-10-08 — — EP disclosed
EP-3920912-B1 TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) GENZYME CORP (US) 2025-06-11 — — EP disclosed
EP-4559918-A2 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2025-05-28 — — EP disclosed
EP-3673906-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2025-05-14 — — EP disclosed
US-12083115-B2 Methods for treating neurological symptoms associated with lysosomal storage diseases GENZYME CORPORATION (US) 2024-09-10 — — US disclosed
WO-2024116127-A1 VENGLUSTAT IN COMBINATION WITH A STRONG OR MODERATE INHIBITOR OF CYP3A4 GENZYME CORPORATION (US) 2024-06-06 — — WO disclosed
WO-2024116127-A1 VENGLUSTAT IN COMBINATION WITH A STRONG OR MODERATE INHIBITOR OF CYP3A4 GENZYME CORPORATION (US) 2024-06-06 — — WO disclosed
EP-4349408-A2 METHODS FOR TREATING PROTEINOPATHIES Genzyme Corporation (US) 2024-04-10 — — EP disclosed
US-9139580-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2015-09-22 — — US disclosed
US-9126993-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2015-09-08 — — US disclosed
US-20140371460-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION 2014-12-18 — — US disclosed
US-20140255381-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2014-09-11 — — US disclosed
CN-103917094-A Glucosylceramide synthase inhibitors GENZYME CORP 2014-07-09 — — CN disclosed
EP-2685986-A2 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2014-01-22 — — EP disclosed
WO-2012129084-A2 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2012-09-27 — — WO disclosed
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER INC. 2008-04-17 — — US disclosed
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds HAMANAKA ERNEST S 2006-10-12 — — US disclosed
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229363-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARA, PPARG, PPARD LMNA 317/4885MAPT 1858/4885MEN1 4859/4885
US-12527776-B2 Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) GBA1, GBA2, GALC LMNA 2738/4885MAPT 3991/4885MEN1 2834/4885
US-20050288340-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD LMNA 319/4885MAPT 1786/4885MEN1 4855/4885
US-12083115-B2 Methods for treating neurological symptoms associated with lysosomal storage diseases GBA1, GBA2, CLN6 LMNA 242/4885MAPT 150/4885MEN1 1953/4885
US-20140371460-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA LMNA 2433/4885MAPT 3133/4885MEN1 1618/4885
US-20140255381-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA LMNA 2433/4885MAPT 3133/4885MEN1 1618/4885
US-20080090829-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PPARA, PPARG, PPARD LMNA 319/4885MAPT 1786/4885MEN1 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.